Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 10/20 | 0.54 |
| ▸ | NOS3 | P29474 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 5/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366773 | 1.00 | NOS2 (0.57) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL28104037 | 1.00 | NOS2 (0.57) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL4362928 | 1.00 | NOS2 (0.57) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736042 | 0.81 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL29613341 | 0.81 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736416 | 0.81 | CYP2C19 (0.59) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL29794337 | 0.79 | CYP2C19 (0.56) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736266 | 0.78 | NPY1R (0.55) | NOS2CYP2C19CYP1A2TSHRGLA | |
| Tilarginine SCHEMBL23099403 | 0.78 | NOS1 (0.69) | NOS2CYP2C19CYP1A2TSHRGLA | |
| SCHEMBL1736695 | 0.78 | NOS2 (0.68) | NOS2CYP2C19CYP1A2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081251-A | Transformation method of L-arginine high-yield strain and application of transformation method in production | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4684026-A1 | STRATEGIES FOR KNOCK-INS AT ROSA26 SAFE HARBOR SITES | Emendobio Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4683643-A1 | STRATEGIES FOR KNOCK-INS AT AAVS1 SAFE HARBOR SITES | Emendobio Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260021141-A1 | Strategies For Knock-Ins At APLP2 Safe Harbor Sites | EMENDOBIO INC. (US) | 2026-01-22 | — | — | US | claimed |
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-12486521-B2 | Platform for expressing protein of interest in liver | TOOLGEN INCORPORATED (KR) | 2025-12-02 | — | — | US | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-12367163-B2 | Analysis of amino acids in body fluid by liquid chromatography—mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-07-22 | — | — | US | claimed |
| WO-2005003351-A1 | DIFFERENTIAL EXPRESSION OF NUCLEIC ACID MOLECULES | CHEMGENEX PHARMACEUTICALS LIMITED (AU) | 2005-01-13 | — | — | WO | claimed |
| WO-2004069866-A1 | THERAPEUTIC MOLECULES | AUTOGEN RESEARCH PTY LTD (AU) | 2004-08-19 | — | — | WO | claimed |
| CN-1457255-A | Compositions of biochemical compounds involved in bioenergy metabolism of cells and methods of use thereof | MATTHIAS RATH (NL) | 2003-11-19 | — | — | CN | claimed |
| US-20020110552-A1 | Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2002-08-15 | — | — | US | claimed |
| WO-2002020005-A1 | USE OF ARGININE IN ENDOSCOPY AND OTHER MEDICAL PROCEDURES | NORGINE EUROPE B.V. (NL) | 2002-03-14 | — | — | WO | claimed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| CN-1091952-A | Cosmetic composition | UNILEVER NV (NL) | 1994-09-14 | — | — | CN | claimed |
| EP-0297294-B1 | PROCESS FOR PREPARING A SOLUTION WITH A HIGH SPECIFIC VOLUME ACTIVITY OF A PROTEIN WITH A TISSUE PLASMINOGEN ACTIVATOR ACTIVITY (T-PA), SOLUTION CONTAINING THE PROTEIN WITH T-PA ACTIVITY AND USE OF THE SOLUTION IN HUMAN AND VETERINARY MEDICINE | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-03-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | NOS2 3496/4885CYP2C19 737/4885CYP1A2 862/4885 |
| US-20260021141-A1 | Strategies For Knock-Ins At APLP2 Safe Harbor Sites | PLPBP, APOB, AGBL2 | NOS2 1685/4885CYP2C19 4713/4885CYP1A2 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.